SRR1335688
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.657
- IL6_JAK_STAT3_SIGNALING+0.545
- INTERFERON_ALPHA_RESPONSE+0.518
- ANGIOGENESIS+0.514
- INFLAMMATORY_RESPONSE+0.496
- INTERFERON_GAMMA_RESPONSE+0.495
- FATTY_ACID_METABOLISM+0.476
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.473
- ESTROGEN_RESPONSE_LATE+0.463
- P53_PATHWAY+0.447
Top 10 suppressed
- MITOTIC_SPINDLE-0.347
- E2F_TARGETS-0.214
- G2M_CHECKPOINT-0.203
- DNA_REPAIR-0.141
- WNT_BETA_CATENIN_SIGNALING-0.108
- HEDGEHOG_SIGNALING-0.092
- PROTEIN_SECRETION-0.077
- SPERMATOGENESIS-0.077
- UV_RESPONSE_DN-0.042
- APICAL_JUNCTION-0.018
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1347688 | GTEX | — | 0.964 |
| 2 | SRR1323196 | GTEX | — | 0.940 |
| 3 | SRR1407315 | GTEX | — | 0.929 |
| 4 | SRR1331597 | GTEX | — | 0.926 |
| 5 | SRR1374414 | GTEX | — | 0.913 |
| 6 | MDT-AP-2001 | Med | Medulloblastoma | 0.913 |
| 7 | MDT-AP-1301 | Med | Medulloblastoma | 0.908 |
| 8 | SRR1440356 | GTEX | — | 0.905 |
| 9 | BS_9BJARSX3 | pleomorphic xanthoastrocytoma(PXA) | — | 0.902 |
| 10 | SRR818971 | GTEX | — | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.657 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.545 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.518 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.514 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.496 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.495 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.476 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.473 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.463 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.447 | Idelalisib | — uncovered |
| COAGULATION | 0.431 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.429 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.428 | Inavolisib | — uncovered |
| HYPOXIA | 0.426 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.420 | Inavolisib | — uncovered |
| MYOGENESIS | 0.404 | Inavolisib | — uncovered |
| APOPTOSIS | 0.402 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.395 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.383 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |